Compare Matson Inc (MATX) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Matson Inc vs Moderna, Inc. — how do they compare? Matson Inc trades at $225.67 (market cap $6.81B), while Moderna, Inc. trades at $225 (market cap $78.65B). The key difference: Moderna, Inc. is far larger — about 11.5× Matson Inc's market cap, and Matson Inc pays a 0.67% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Matson Inc for 23 Days and Moderna, Inc. for 59 Days on average.
| MATX | MRNA | |
|---|---|---|
Market Cap | $6.81B | $78.65B |
Volume | 255,080 | 37,373,437 |
Sector | Industrials | Health |
52-Week High | $238.60 | $203.46 |
52-Week Low | $88.05 | $22.36 |
Typical Hold Time | 23 Days | 59 Days |
Enterprise Value | $7.41B | $74.80B |
Dividend Yield | 0.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Matson (MATX) trades at $225.67, up 1.23% with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with Q2 2026 EPS of $4.27 beating estimates by 12.7% and raising full-year guidance. Revenue growth continues with 2026 projections of $3.5B and net profit margins above 13%. Recent institutional buying from Bank of New York Mellon and Deutsche Bank highlights confidence in the shipping company's prospects.
MATX presents a compelling investment case with strong earnings momentum, reasonable valuation (P/E 15.37), and positive analyst sentiment (67% buy ratings). Key risks include freight market cyclicality and competitive pressures. The stock's 27.3% upside potential based on analyst targets and consistent dividend payments ($0.38 declared for H2-26) support a favorable outlook for value-oriented investors seeking transportation sector exposure.
Moderna (MRNA) trades at $197.00, up 0.26% on the day, with technical indicators showing a bullish trend and strong momentum. The stock has rallied over 500% in 2026, driven by positive clinical updates for its cancer vaccine pipeline and inclusion in the Nasdaq-100 index effective October 9, 2026. However, fundamentals remain challenging with revenue declining from $18.9B in 2022 to $1.9B in 2025 and negative net income margins exceeding 140%.
While technical momentum and pipeline optimism support near-term upside, valuation appears stretched with P/S of 35.08 and negative profitability metrics. Key risks include execution on non-COVID products, competitive pressure, and sustainability of recent gains. Analyst consensus is cautious with only 28% buy ratings and $115.70 price target suggesting significant downside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Matson Inc
Matson, Inc. is an American shipping and logistics company primarily operating in the Pacific. The company provides ocean transportation services, including container, automobile, and general cargo, particularly between the U.S. West Coast, Hawaii, Alaska, and Guam. Matson also offers logistics services, including warehousing, less-than-container load (LCL) consolidation, and supply chain management, making it a critical service provider for businesses operating across the Pacific region.
Read more on MATX →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
